Choriogonadotropin Alfa

Brand names: Ovidrel
Drug class: Antineoplastic Agents

Usage of Choriogonadotropin Alfa

Female Infertility

Used in conjunction with other infertility agents (e.g., gonadotropin-releasing hormone agonist, FSH) for induction of final follicular maturation and early luteinization in ovulatory, infertile women during assisted reproductive technology (ART) programs.

Use in patients with tubal obstruction only if participating in ART programs.

Choriogonadotropin alfa (r-hCG) is equivalent to urinary-derived hCG with regard to number of oocytes recovered, fertilized oocytes or embryos, and live births.

Used in conjunction with follicle-stimulating agent to induce ovulation in anovulatory, infertile women in whom anovulation is functional and not due to primary ovarian failure.

Choriogonadotropin alfa (r-hCG) is similar to urinary-derived hCG with regard to ovulation rates.

Relate drugs

How to use Choriogonadotropin Alfa

General

  • Should be prescribed only by clinicians experienced in infertility treatment and who are familiar with cautions, precautions, and contraindications associated with such therapy.
  • Prior to treatment initiation with choriogonadotropin alfa, perform a thorough gynecologic and endocrinologic evaluation; assess pelvic anatomy and rule out early pregnancy, primary ovarian failure (as indicated by increased serum concentrations of FSH and LH and low serum estrogen concentrations), and neoplasms. (See Contraindications under Cautions.) Perform a thorough diagnostic evaluation in patients who demonstrate abnormal uterine bleeding and other signs of endometrial abnormalities. (See Contraindications under Cautions.) Evaluate partner’s infertility.
  • When ultrasound assessment and serum estradiol concentrations show sufficient follicular maturation, administer choriogonadotropin alfa 1 day after last dose of follicle-stimulating agent to complete final follicular maturation and induce ovulation.
  • Withhold further follicle-stimulating therapy and delay or withhold choriogonadotropin alfa if ovaries show an excessive response to treatment with gonadotropins because of increased risk of ovarian hyperstimulation syndrome (OHSS). (See Ovarian Hyperstimulation Syndrome under Cautions.)
  • Encourage daily sexual intercourse beginning 1 day prior to administration of choriogonadotropin alfa until ovulation occurs (as determined by rise in basal body temperature, increase in serum progesterone concentrations, and menstruation following shift in basal body temperature). (See Adequate Patient Evaluation and Monitoring under Cautions.)
  • Examine ovaries by ultrasound for persistent cysts, particularly when attempts at stimulation of ovulation follow immediately after unsuccessful stimulated cycle.

    • Administration

    Sub-Q Administration

    Administer by sub-Q injection, generally into abdomen using commercially available prefilled syringe; may be self-administered by patient.

    Dosage

    Adults

    Female Infertility ART Sub-Q

    250 mcg, given 1 day following last dose of follicle-stimulating agent. (See General under Dosage and Administration.)

    Ovulation Induction Sub-Q

    250 mcg, given 1 day following last dose of follicle-stimulating agent. (See General under Dosage and Administration.)

    If stimulation of ovulation is unsuccessful, adjust dosage of follicle-stimulating agent administered in subsequent cycles based on woman’s response in preceding cycle.

    Prescribing Limits

    Adults

    Female Infertility Sub-Q

    Maximum 500-mcg single dose studied in clinical trials.

    Warnings

    Contraindications

  • Known hypersensitivity to human chorionic gonadotropin preparations (including urinary-derived hCG) or any ingredient in formulation.
  • Primary ovarian failure.
  • Uncontrolled thyroid or adrenal dysfunction.
  • Uncontrolled organic intracranial lesions (e.g., pituitary neoplasms).
  • Abnormal intrauterine or vaginal bleeding of undetermined origin.
  • Ovarian cysts or enlargement of undetermined origin.
  • Sex-hormone-dependent neoplasms of reproductive tract and accessory organs.
  • Pregnancy.

    • Warnings/Precautions

    Warnings

    Ovarian Enlargement

    Risk of mild to moderate uncomplicated ovarian enlargement; may be accompanied by abdominal distention and/or pain, but generally regresses without treatment within 2–3 weeks. Careful monitoring of ovarian response recommended.

    If ovaries are abnormally enlarged during controlled ovarian stimulation, withhold choriogonadotropin alfa during current course of therapy to minimize risk of OHSS. (See Ovarian Hyperstimulation Syndrome under Cautions.)

    Ovarian Hyperstimulation Syndrome

    Risk of potentially severe OHSS, characterized by apparent dramatic increase in vascular permeability that may result in rapid accumulation of fluid in peritoneal cavity, thorax, and potentially, pericardium.

    May progress rapidly (within 24 hours to several days). Initial manifestations include severe pelvic pain, nausea, vomiting, and weight gain. Other symptoms include abdominal pain/distention, diarrhea, severe ovarian enlargement, dyspnea, and oliguria. Hypovolemia, hemoconcentration, electrolyte imbalances, ascites, hemoperitoneum, pleural effusions, hydrothorax, acute pulmonary distress, and thromboembolic events may occur.

    Transient liver function test abnormalities, which may be accompanied by morphologic changes (as detected by liver biopsy), reported.

    Occurs most often after completion of gonadotropin therapy, reaching maximum severity after 7–10 days; usually resolves spontaneously with onset of menses. Monitor patients for ≥2 weeks after hCG administration. OHSS may be more severe and protracted if pregnancy occurs.

    If severe OHSS develops, discontinue therapy, hospitalize patient, and consult clinician experienced in management of OHSS or fluid and electrolyte imbalances.

    Multiple Births

    Multiple ovulations resulting in multiple gestations reported in 30.9 or 13.3% of women during ART programs or ovulation induction, respectively.

    Risk of multiple births correlates with number of embryos transferred.

    Thromboembolism

    Potential for arterial thromboembolism exists.

    Fetal/Neonatal Morbidity and Mortality

    May cause fetal harm; exclude pregnancy before initiating treatment.

    Animal studies indicate adverse effects on pregnancy outcomes and/or labor. (See Contraindications under Cautions.)

    General Precautions

    Adequate Patient Evaluation and Monitoring

    Administer only under supervision of qualified clinicians experienced in fertility disorders and interpretation of indices of ovulation.

    Monitor follicular development (e.g., using transvaginal ultrasound, serum estradiol concentrations) to correctly identify follicular maturation, determine timing of choriogonadotropin alfa administration, detect ovarian enlargement, and minimize risks of OHSS and multiple gestation.

    Obtain clinical confirmation of ovulation from direct and indirect indices of progesterone production, including rise in basal body temperature, an increase in serum progesterone concentrations, and menstruation following shift in basal body temperature. Sonographic evidence of ovulation includes findings of fluid in cul-de-sac, ovarian stigmata, collapsed follicle, and secretory endometrium.

    Specific Populations

    Pregnancy

    Category X. (See Fetal/Neonatal Morbidity and Mortality and also Contraindications under Cautions.)

    Lactation

    Not known whether choriogonadotropin alfa is distributed into milk. Use caution.

    Pediatric Use

    Safety and efficacy not established.

    Geriatric Use

    Safety and efficacy not established.

    Hepatic Impairment

    Safety and efficacy not established.

    Renal Impairment

    Safety and efficacy not established.

    Common Adverse Effects

    ART: Injection site reactions (i.e., pain, bruising), abdominal pain, nausea, vomiting, postoperative pain.

    Ovulation induction: Injection site reactions (i.e., pain, inflammation, bruising, other injection site reaction), ovarian cysts, ovarian hyperstimulation, abdominal pain.

    What other drugs will affect Choriogonadotropin Alfa

    No formal drug interaction studies to date.

    Laboratory Tests

    Test

    Interaction

    Comments

    Radioimmunoassays for gonadotropins

    Possible cross-reaction with radioimmunoassays for gonadotropins, particularly LH

    Individual laboratories should establish degree of cross-reactivity with their gonadotropin assay

    When requesting gonadotropin concentration determinations, inform laboratory of choriogonadotropin alfa therapy

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords